Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Meningococcal vaccine development: a novel approach.

P C Fusco1, M S Blake, F Michon

  • 1North American Vaccine, Inc., 12103 Indian Creek Court Beltsville, MD 20705, USA.

Expert Opinion on Investigational Drugs
|July 5, 2005
PubMed
Summary

A new trivalent meningococcal vaccine combining N-propionyl group B meningococcal polysaccharide with recombinant outer membrane porin B (rPorB) shows promise. This conjugate vaccine elicits bactericidal antibodies against serogroups A, B, and C, potentially offering broad protection against meningitis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multicolor strategies for investigating clonal expansion and tissue plasticity.

Cellular and molecular life sciences : CMLS·2022
Same author

<i>Sox2</i> Controls Periderm and Rugae Development to Inhibit Oral Adhesions.

Journal of dental research·2020
Same author

Studies of Porins: Spontaneously Transferred from Whole Cells and Reconstituted from Purified Proteins of Neisseria gonorrhoeae and Neisseria meningitidis.

Biophysical journal·2009
Same author

What is the biological basis of pattern formation of skin lesions?

Experimental dermatology·2006
Same author

Identification of peptides that mimic the pertussis toxin binding site on bovine fetuin.

Applied and environmental microbiology·2003
Same author

A one-step method for genetic transformation of non-piliated Neisseria meningitidis.

Journal of microbiological methods·2002

Area of Science:

  • Vaccinology
  • Microbiology
  • Immunology

Background:

  • Neisseria meningitidis causes meningitis worldwide.
  • Current capsular polysaccharide (CPS) vaccines are T-cell independent, limiting efficacy in infants and long-term protection.
  • Group B meningococci (GBM) are a major cause of disease, but their poorly immunogenic polysialic acid CPS presents a vaccination challenge.

Purpose of the Study:

  • To develop a more effective meningococcal vaccine, particularly against serogroup B.
  • To enhance immunogenicity and induce bactericidal (BC) antibodies against meningococcal CPS.
  • To create a trivalent vaccine covering serogroups A, B, and C.

Main Methods:

  • N-propionyl modification of GBM polysaccharide (GBMP) to improve immunogenicity.

Related Experiment Videos

  • Conjugation of modified GBMP to recombinant GBM class 3 porin (rPorB) via reductive amination.
  • Combination with similar CPS-rPorB conjugates for serogroups A and C to form a trivalent vaccine.

    • Main Results:

    • The N-propionyl modification of GBMP enhanced immunogenicity.
    • Conjugation to rPorB modulated the immune response, promoting CPS-specific BC antibodies.
    • The trivalent A/B/C conjugate vaccine was safe and highly immunogenic in mice and non-human primates.

    Conclusions:

    • The developed trivalent meningococcal vaccine generates robust, CPS-specific BC antibodies against serogroups A, B, and C.
    • This conjugate vaccine strategy shows potential for providing broad, long-lasting protection against meningococcal disease globally.